Welcome to our dedicated page for HeartSciences SEC filings (Ticker: HSCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HeartSciences Inc. (HSCS) SEC filings page provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq‑listed healthcare information technology and medical technology company, HeartSciences uses these filings to report on its financial condition, capital structure, and material corporate events related to its AI‑ECG platforms and devices.
Through forms such as the annual report on Form 10‑K and quarterly reports on Form 10‑Q, HeartSciences outlines its business focus on applying artificial intelligence to ECGs/EKGs, describes its MyoVista Insights cloud‑native ECG management platform and MyoVista wavECG device, and provides detailed financial statements and risk factor discussions. Current reports on Form 8‑K disclose specific events, including regulatory milestones, financing transactions, loan amendments, equity offerings, and notices related to Nasdaq listing requirements.
Investors can also review filings that discuss the company’s capital raising activities, such as Regulation A offerings, warrant and preferred stock issuances, and debt exchanges, as well as governance‑related items like indemnification agreements for directors and officers. These documents help explain how HeartSciences funds the development and commercialization of its AI‑ECG technologies and manages its obligations.
On Stock Titan, SEC filings for HSCS are supplemented with AI‑powered summaries that highlight key points from lengthy documents, helping readers quickly understand the significance of each filing. Users can follow new 10‑K, 10‑Q, and 8‑K submissions, along with other relevant forms, to stay informed about HeartSciences’ reported financial results, regulatory disclosures, and corporate actions.
HeartSciences Inc. filed a Form S-8 to register 209,857 shares of common stock for issuance under its 2023 Equity Incentive Plan, reflecting the plan’s Evergreen Provision increase as of May 1, 2025. The filing also includes a reoffer prospectus of up to 252,561 shares that may be resold from time to time by certain affiliates, inclusive of the newly reserved shares.
The company will not receive proceeds from affiliate resales; it would receive cash only if outstanding employee stock options are exercised. Separately, on July 9, 2025, the company increased the plan’s reserve to 1,000,000 shares plus Evergreen, a change that has not yet been approved by shareholders.
As context, shares of common stock outstanding were 3,071,135 prior to the offering and 3,323,696 after, as shown in the prospectus table; this is a baseline share count, not the amount being registered for issuance.
HeartSciences Inc. extended the maturity of its existing $500,000 secured promissory note with Front Range Ventures to September 30, 2026, keeping the 12% annual interest and revising how accrued interest is paid. The company will pay interest accrued through September 30, 2025 on or before that date, with all later accrued interest due at maturity, and it can prepay at least $50,000 at a time, applied first to interest and then principal.
Through a qualified Regulation A offering of up to 4,285,714 units at $3.50 per unit, the company has raised $6.7 million in gross proceeds from 1,912,383 units as of October 1, 2025. Each unit includes one share of Series D preferred stock and one warrant to buy common stock at $5.00 per share, and holders have converted 1,331,044 Series D preferred shares into the same number of common shares. The company also exchanged $2,060,000 of principal and $45,000 of accrued interest on an unsecured note for 597,578 common shares, and had 3,069,635 common shares outstanding as of October 1, 2025.
HeartSciences Inc. reports that it has regained compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement, which calls for at least $2.5 million in stockholders’ equity for companies on The Nasdaq Capital Market. Nasdaq’s Listing Qualifications Staff notified the company on September 16, 2025, that the issue is resolved and the matter is now closed. HeartSciences had previously submitted a plan to Nasdaq explaining how it would regain and maintain compliance after falling below the required equity level.